Advertisement

Volume 131, Issue 25

 

 

June 21, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Critical role for TRAIL-mediated activation in persistence of T- and NK-cell LGL leukemia. See the article by Yang et al.

TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia
The investigators identify and delineate a critical mechanism that sustains T- and NK-cell large granular lymphocyte (LGL) leukemia via constitutive TRAIL-mediated activation of the NF-κB pathway. They also show that these novel observations have important potential therapeutic implications.


TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma
The researchers report a pathway regulating p53 accumulation in lymphoma via TRRAP. TRRAP, a constituent of multiple histone acetyltransferase complexes, acetylates and stabilizes p53 induced by DNA damage in lymphoma.


Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase
The anticoagulant warfarin inhibits vitamin K oxidoreductase complex subunit 1 (VKORC1), thereby dampening the carboxylation and the procoagulant potential of vitamin K–dependent coagulation factors. The authors uncovered the detailed molecular mechanism by which warfarin inhibits VKORC1.


iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
This Special Report updates the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. The updated guidelines are a key resource for physicians dealing with patients with CLL as well as scientists with an interest in the disease.


Biology and treatment of Richter syndrome
In a timely review, the authors discuss the biology and treatment of Richter syndrome.


How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions
Delayed-type transfusion reactions in sickle cell disease are frequent and fundamental clinical management challenges. In this How I Treat article, the authors present their preventive and therapeutic approaches in clinical practice.


High NPM1–mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
This study explores the substantial prognostic impact of high allelic burden of NPM1 gene mutations in the context of particular coexisting gene mutations in acute myeloid leukemia (AML).


Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
This paper presents the incidence and outcomes of patients who were treated in leukemia clinical trials and reports that patients classified as ineligible for trial enrollment have outcomes similar to those of the eligible patients.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.